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molecular weight of 70,000–85,000 in immunoblots from 
human pituitary. After enzymatic deglycosylation, the size of 
this band decreased to a molecular weight of 45,000. Tissue 
immunostaining was completely abolished by pre-adsorp-
tion of UMB-5 with its immunizing peptide. In addition, 
UMB-5 detected distinct cell populations in human tissues 
like pancreatic islands, anterior pituitary, adrenal cortex, ad-
renal medulla, and enteric ganglia, similar to that seen with 
a rabbit polyclonal antibody generated against a different 
carboxyl-terminal epitope of the sst 3 receptor. In a compara-
tive immunohistochemical study, UMB-5 yielded predomi-
nant plasma membrane staining in the majority of pituitary 
adenomas, pheochromocytomas, and a subset of neuroen-
docrine tumors. The sst 3 receptor was also present in many 
glioblastomas, pancreatic, breast, cervix, and ovarian carci-
nomas.  Conclusion: The rabbit monoclonal antibody UMB-5 
may prove of great value in the identification of sst 3 -express-
ing tumors during routine histopathological examinations. 
Given its unique trafficking properties, these tumors may be 
potential candidates for sst 3 -directed receptor radiotherapy. 
 Copyright © 2012 S. Karger AG, Basel 
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 Abstract 
 Background: Among the five somatostatin receptors (sst 1 -
sst 5 ), the sst 3 receptor displays a distinct pharmacological 
profile. Like sst 2 , the sst 3 receptor efficiently internalizes ra-
diolabeled somatostatin analogs. Unlike sst 2 , however, inter-
nalized sst 3 receptors are rapidly transferred to lysosomes 
for degradation. Apart from this, very little is known about 
the clinical relevance of the sst 3 receptor, which may in part 
be due to the lack of specific monoclonal sst 3 antibodies. 
 Methods: Here, we have extensively characterized the novel 
rabbit monoclonal anti-human sst 3 antibody UMB-5 using 
transfected cells and receptor-expressing tissues. UMB-5 
was then subjected to immunohistochemical staining of a 
series of 190 formalin-fixed, paraffin-embedded normal and 
neoplastic human tissues.  Results: Specificity of UMB-5 was 
demonstrated by detection of a broad band migrating at a 
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 Introduction 
 Somatostatin is a cyclic neuropeptide that inhibits the 
secretion of a large number of hormones from the ante-
rior pituitary, pancreas, and endocrine cells within the 
gastrointestinal tract, regulates neurotransmission both 
in the brain and in the peripheral nervous system, and 
exerts antiproliferative effects. Additionally, it causes a 
reduction of gastrointestinal tract motility and gallblad-
der contractility and plays a regulatory role in the im-
mune system  [1–3] . The biological functions of soma-
tostatin are mediated via a family of G-protein-coupled 
receptors, sst 1 to sst 5 . For sst 2 two splice variants have 
been identified in rodents, the unspliced sst 2A and the 
spliced sst 2B , carrying a different carboxyl terminus. In a 
varying pattern and density, somatostatin receptors are 
present throughout the body, including brain, pituitary 
gland, neuroendocrine cells of the gastrointestinal tract 
and pancreas, thyroid gland, adrenals, and immune sys-
tem  [1–3] . Somatostatin receptors have also been found in 
many tumors, including pituitary adenomas and neuro-
endocrine tumors  [4, 5] , where they mediate inhibitory 
effects on both hormone secretion and tumor growth  [6, 
7] . Apart from the tissue distribution, sst receptors differ 
also in their pharmacological profile for synthetic soma-
tostatin analogs, in their regulation of intracellular sig-
naling pathways, and in their biological functions  [8–10] . 
For the sst 3 receptor it has been shown that upon its acti-
vation apoptosis can be induced, which displays a unique 
function among the sst receptor family. Consequently, it 
has been reported that sst 3 stimulation results in an in-
duction of two important pro-apoptotic proteins, p53 
and Bax, as well as in a translocation of protein tyrosine 
phosphatase (PTP) to the plasma membrane  [8, 11, 12] . 
On the other hand, it has been demonstrated that the ac-
tivated sst 3 receptor mediates an inhibition of tumor an-
giogenesis and growth, via regulation of endothelial ni-
tric oxide synthase (eNOS) and mitogen-activated pro-
tein kinase (MAPK) activities  [13] . Thus, the sst 3 receptor 
is of considerable interest as a pharmacological target for 
tumor therapy. Additionally, the sst 3 receptor seems to be 
involved in the control of permeability and biogenesis of 
epithelial tight junctions and, as a consequence, in the 
regulation of paracellular conductance  [14] . Also with re-
spect to its regulation, the sst 3 receptor seems to be dif-
ferent from other members of the sst receptor family. 
Both human and rat sst 3 have been shown to internalize 
rapidly after agonist stimulation and subsequent phos-
phorylation at the carboxyl terminal tail through a   -
arrestin-clathrin-dependent pathway. In contrast to the 
sst 2A receptor, however, only part of the internalized re-
ceptors are redistributed to the plasma membrane after 
agonist withdrawal. A large proportion of the receptor is 
sequestered into intracellular clusters of larger vesicles 
and degraded after multiple ubiquitination, thus leading 
to profound downregulation of the sst 3 receptor after sus-
tained agonist stimulation  [10, 15] . This may be the mo-
lecular basis for the observation that, after intravenous 
injection of radiolabeled sst 2 - or sst 3 -receptor ligands into 
mice bearing sst 2 - or sst 3 -expressing tumors, with a sst 3 -
directed radioligand a much more pronounced and sus-
tained uptake was observed than with a sst 2 -directed ra-
dioligand  [16, 17] . Thus, the sst 3 receptor may be of par-
ticular interest as a target for receptor radiotherapy of 
human tumors.
 However, in comparison to sst 2 and to sst 5 receptors, 
much less is known about the precise tissue distribution, 
downstream signaling, and function of the sst 3 receptor. 
This may be in part due to the lack of suitable monoclonal 
antibodies, available in sufficient amounts for immuno-
histochemical staining of formalin-fixed, paraffin-em-
bedded human tissue samples obtained during routine 
histopathological preparations.
 Recently, we have extensively characterized two novel 
rabbit monoclonal antibodies against the sst 2A receptor 
and against the human sst 5 receptor named UMB-1 and 
UMB-4, respectively. We have shown that both antibod-
ies selectively detect their cognate receptor in crude 
membrane extracts from sst receptor-expressing cells 
and tissues and that they are excellently suited for the as-
sessment of sst 2A or sst 5 expression in fixed human tissue 
samples  [18–20] . Given the numerous advantages of a 
rabbit monoclonal antibody compared with the current-
ly available polyclonal anti-human sst 3 antisera, we have 
now generated and thoroughly characterized a rabbit 
monoclonal antibody directed against the carboxyl-ter-
minal tail of the human sst 3 receptor. We have then used 
the novel antibody UMB-5 to evaluate the prevalence and 
cellular localization of sst 3 in a large series of formalin-
fixed, paraffin-embedded human normal and neoplastic 
tissue samples.
 Materials and Methods 
 Tissue Specimens for Immunohistochemistry 
 A total of 190 human tumor specimens were obtained from the 
Departments of Pathology of the Charité Universitätsmedizin 
Berlin, Ernst Moritz Arndt University Greifswald, Otto von Gue-
ricke University Magdeburg, and Marienkrankenhaus Hamburg, 
Germany. Permission was obtained from the local ethics commit-
 Novel Rabbit Monoclonal Anti-Human 
sst 3 Antibody UMB-5 
 Neuroendocrinology 2012;96:301–310 303
tees to access material from the pathology archives. The following 
tumor species were investigated: pituitary adenoma (n = 41, clas-
sified as non-functioning adenoma [n = 6], ACTH-producing ad-
enoma [n = 8], and GH-producing adenoma [n = 27]), glioblas-
toma (n = 6), pancreatic adenocarcinoma (n = 10), renal clear cell 
carcinoma (n = 9), pheochromocytoma (n = 13), neuroendocrine 
tumors of the lung (n = 2), of the gut (n = 31), and pancreatic in-
sulinoma (n = 5) as well as lymph node metastases (n = 16) and 
liver metastases (n = 13) from neuroendocrine tumors, prostate 
adenocarcinoma (n = 9), breast carcinoma (n = 12, classified as 
invasive ductal carcinoma [n = 8], invasive lobular carcinoma 
[n = 2], and solid neuroendocrine carcinoma of the breast [n = 2]), 
cervix carcinoma (n = 11, classified as squamous cell carcinoma 
[n = 7], adenocarcinoma [n = 3], and neuroendocrine tumor [n = 
1]), and ovarian tumors (n = 12, classified as serous-papillary 
ovarian adenocarcinoma [n = 5], granulosa cell tumor [n = 4], 
rhabdomyosarcoma [n = 2], and Brenner tumor [n = 1]). Many of 
the tumor specimens contained adjacent non-malignant tissue, 
which enabled us to analyze the distribution of sst 3 in normal tis-
sues as well. Additionally, tumor-free human tissue samples from 
pituitary, liver, pancreas, kidney, and different parts of the gut 
were also evaluated and the staining patterns compared to those 
seen in the tissues surrounding, e.g., renal clear cell carcinoma or 
neuroendocrine tumors and their metastases. In no case, differ-
ences were observed. All tissue specimens had been fixed in for-
malin and embedded in paraffin. In addition, pituitary samples 
from human autopsy were obtained from the Department of Neu-
ropathology, Otto von Guericke University Magdeburg, Germa-
ny. Samples were frozen in liquid nitrogen and stored at –80   °   C 
until Western blot analysis.
 Antibodies 
 The rabbit monoclonal antibody UMB-5 was generated 
against the carboxyl-terminal tail of the human sst 3 and custom 
produced by Epitomics (Burlingame, Calif., USA). The identity of 
the peptide used for immunizations of the rabbits was 
QLLPQEASTGEKSSTMRISYL, which corresponds to the resi-
dues 398–418 of the human sst 3 receptor. This sequence is unique 
for the human sst 3 receptor. Consequently, UMB-5 does not 
cross-react with rat or mouse sst3 receptors. The peptide was pu-
rified and coupled to keyhole limpet hemocyanin. The conjugate 
was mixed 1: 1 with Freund’s adjuvant and injected into four rab-
bits for antiserum production. Injection was performed at 4-week 
intervals, and serum was obtained from the second injection on. 
The specificity of the antisera was initially tested using Dot blot 
analysis. At the optimal time point of antibody production, the 
animals were sacrificed and rabbit hybridoma cells were pro-
duced by fusing B-cells from the spleen with myeloma cells.
 The immunohistochemical staining pattern of UMB-5 was 
compared to that of the affinity-purified rabbit polyclonal anti-
human sst 3 antibody {4823}, which is directed to a different epi-
tope, QERPPSRVA, corresponding to the residues 385–393 of the 
human sst 3 receptor. These residues are located in close proxim-
ity to the carboxyl terminus of human sst 3 ( fig. 1 ). For comparison 
of the expression patterns, adjacent sections of the pituitary ade-
noma samples were also stained with the rabbit monoclonal anti-
sst 2A antibody UMB-1 or the rabbit monoclonal anti-human sst 5 
antibody UMB-4. The polyclonal antibody {4823} as well as the 
monoclonal antibodies UMB-1 and UMB-4 have been extensive-
ly characterized previously  [18–21] .
 Western Blot Analysis 
 Human embryonic kidney 293 (HEK-293) cells stably trans-
fected with human sst 2A , sst 3 or sst 5 as well as pituitary samples 
from human autopsy were lysed in detergent buffer (20 m M 
Hepes, pH 7.4, 150 m M NaCl, 5 m M EDTA, 1% Triton X-100, 10% 
glycerol, 0.1% SDS, 0.2 m M phenylmethylsulfonyl fluoride, 10 mg/
ml leupeptin, 1 mg/ml pepstatin A, 1 mg/ml aprotinin, and 10 mg/
ml bacitracin). Receptors were enriched using wheat germ lectin 
agarose beads as described previously  [22] . When indicated, so-
matostatin receptors were deglycosylated using peptide:  N -glyco-
sidase F (PNGase F) according to the manufacturer’s instructions 
(New England BioLabs, Beverly, Mass., USA). Samples were then 
subjected to 7.5% SDS polyacrylamide gel electrophoresis and im-
munoblotted onto PVDF membranes. Blots were incubated with 
the rabbit monoclonal anti-human sst 3 antibody UMB-5 (dilution 
1: 200), followed by a peroxidase-conjugated secondary anti-rab-
bit antibody (Santa Cruz Biotechnology, Santa Cruz, Calif., USA; 
dilution 1: 5,000) and enhanced chemiluminescence detection 
(Amersham, Braunschweig, Germany). 
 Immunocytochemistry 
 Stably sst 3 -transfected HEK-293 cells were grown on cover-
slips overnight and either not exposed or exposed to 1   M soma-
tostatin-14 (SS-14), 1   M octreotide or 1   M pasireotide for 30 min 
(source of octreotide and pasireotide: Novartis, Basel, Switzer-
land). They were subsequently fixed and incubated with the rabbit 
monoclonal anti-human sst 3 antibody UMB-5 (dilution: 1: 100) at 
4    °    C overnight followed by an incubation with Alexa Fluor 
488-conjugated secondary antibody (Invitrogen, Karlsruhe, Ger-
many; dilution: 1: 750). Specimens were mounted as described 
previously  [22] and examined using a Zeiss LSM 510 Meta laser 
scanning confocal microscope.
 Immunohistochemistry 
 Five-micrometer sections were prepared from paraffin blocks 
and floated onto positively charged slides. Immunostaining was 
performed by an indirect peroxidase labeling method as de-
scribed previously  [23] . Briefly, sections were dewaxed, micro-
waved in 10 m M citric acid (pH 6.0) for 16 min at 600 W, and then 
incubated either with the rabbit monoclonal anti-human sst 3 an-
tibody UMB-5 (dilution 1: 20) or with the rabbit polyclonal anti-
human sst 3 antibody {4823} (concentration 0.1   g/ml), the rabbit 
monoclonal anti-sst 2A antibody UMB-1 or the rabbit monoclonal 
anti-human sst 5 antibody UMB-4 (dilution 1: 10 each) overnight 
at 4  °  C. Detection of the primary antibody was performed using a 
biotinylated anti-rabbit IgG followed by an incubation with per-
oxidase-conjugated avidin (Vector ABC ‘Elite’ kit, Vector Labo-
ratories, Burlingame, Calif., USA). Binding of the primary anti-
body was visualized using 3-amino-9-ethylcarbazole (AEC) in 
acetate buffer (BioGenex, San Ramon, Calif., USA). Sections were 
then rinsed, counterstained with Mayer’s hematoxylin and 
mounted in VectamountiTM mounting medium (Vector Laborato-
ries). For immunohistochemical controls, UMB-5 was either 
omitted or adsorbed for 2 h at room temperature with 10   g/ml 
of the peptide used for immunizations.
 Evaluation of the Staining Patterns 
 Two independent investigators evaluated all immunohisto-
chemical stainings. In the case of a discrepancy in the scoring 
between the two investigators, a final decision was achieved by 
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consensus. All sections were scored by means of the immunore-
activity score (IRS) according to Remmele and Stegner  [24] , both 
noting the intensity of the color as well as the percentage of cells 
showing a positive staining. The IRS, comprising score values be-
tween 0 and 12, was calculated as follows: score [percentage of 
positive cells]  ! score [intensity of staining] = IRS; score [per-
centage of positive cells]: no positive cells (0);  ! 10% (1); 10–50% 
(2); 51–80% (3);  1 80% (4); score [intensity of staining]: no staining 
(0); mild (1); moderate (2); strong (3). The classification of the 
staining as ‘strong’ was based on the intensity of the staining of 
two positive control locations, pancreatic islets and pheochromo-
cytomas ( fig. 1 c, d), known from the literature as strongly express-
ing the sst 3 receptor. Only a slight intensity of staining was clas-
sified as ‘mild’ (see, e.g.,  fig. 2 : sst 2 expression in ACTH adenoma) 
and the staining intensity between ‘mild’ and ‘strong’ as ‘moder-
ate’.
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 Fig. 1. Immunohistochemical localization of sst 3 in human nor-
mal and neoplastic tissues using the monoclonal antibody 
UMB-5.  A Schematic representation of the sst 3 receptor indicat-
ing the different carboxyl-terminal epitopes of the rabbit poly-
clonal anti-human sst 3 antibody {4823} and the rabbit monoclo-
nal anti-human sst 3 antibody UMB-5.  B Sections were dewaxed, 
microwaved in citric acid, and incubated with either the rabbit 
polyclonal anti-human sst 3 antibody {4823} ( a ,  b ) or the rabbit 
monoclonal anti-human sst 3 antibody UMB-5 ( c–h ). Sections 
were then sequentially treated with biotinylated rabbit IgG and 
peroxidase-conjugated avidin. Finally, color was developed by 
incubation in AEC, and sections were counterstained with he-
matoxylin.  Inset For adsorption controls, UMB-5 was incubated 
with 10   g/ml of the peptide used for immunizations. Note that 
both the monoclonal antibody UMB-5 and the polyclonal anti-
body {4823} yielded similar staining patterns.  Arrows = mast 
cells; arrowheads = enteric ganglion cells. Scale bar ( a–h ) =
250   m. 
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 Results 
 Characterization of the Rabbit Monoclonal 
Anti-Human sst 3 Antibody UMB-5 
 The specificity of UMB-5 was initially monitored us-
ing Western blot analysis. When membrane prepara-
tions from HEK-293 cells stably transfected with human 
sst 3 , sst 2A or sst 5 were electrophoretically separated and 
immunoblotted onto nitrocellulose, UMB-5 revealed a 
broad band migrating at M r 70,000–90,000 in sst 3 -trans-
fected but not in sst 2A - or sst 5 -transfected cells ( fig. 3 a). 
UMB-5 was then characterized by immunocytochemi-
cal staining of sst 3 -transfected cells. When HEK-293 
cells stably expressing sst 3 were stained with UMB-5, a 
distinct immunofluorescence localized at the level of the 
plasma membrane was detected ( fig.  3 c). Incubation 
with somatostatin-14 (SS-14) induced a translocation of 
the receptor immunoreactivity from the plasma mem-
brane into the cytosol, indicating agonist-induced endo-
cytosis. A similar result was obtained with pasireotide, 
whereas saturating concentrations of octreotide were 
not able to stimulate the internalization of sst 3 receptors 
under otherwise identical conditions ( fig.  3 c). UMB-5 
was also tested for possible cross-reactivity with other 
proteins present in human tissues. When membrane 
preparations from pituitaries from human autopsy were 
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 Fig. 2. Immunohistochemical localization of sst 2A , sst 3 , and sst 5 
in human pituitary adenomas. Sections of different types of hu-
man pituitary adenomas [non-functioning adenomas (= inactive 
adenomas; upper panel), ACTH-producing adenomas (middle 
panel), and GH-producing adenomas (lower panel)] were de-
waxed, microwaved in citric acid, and incubated with either the 
rabbit monoclonal anti-sst 2 antibody UMB-1 (left panel), the rab-
bit monoclonal anti-human sst 3 antibody UMB-5 (middle panel), 
or the rabbit monoclonal anti-human sst 5 antibody UMB-4 (right 
panel). Sections were then sequentially treated with biotinylated 
anti-rabbit IgG and peroxidase-conjugated avidin. Finally, color 
was developed by incubation in AEC, and sections were counter-
stained with hematoxylin. Note that, in contrast to sst 2 and sst 5 , 
sst 3 was present in all three types of human adenomas and that 
the immunostaining for sst 2 , sst 3 as well as sst 5 was predominant-
ly localized at the plasma membrane. Scale bar = 500   m. 
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electrophoretically separated and blotted onto PVDF 
membranes, UMB-5 detected a broad band migrating at 
M r  72,000–85,000 ( fig. 3 b, left panel). To test the hypoth-
esis that the bands detected in human pituitary samples 
would represent the glycosylated sst 3 receptor, N-glyco-
sylated proteins were enriched by means of lectin aga-
rose beads and then subjected to enzymatic deglycosyl-
ation using PNGase F. In fact, after deglycosylation 
UMB-5 detected a distinct band migrating at M r 
  45,000, the expected molecular weight of the deglyco-
sylated receptor ( fig. 3 b, right panel).
 Immunohistochemical Localization of sst 3 in Human 
Tumors and in Their Tissues of Origin 
 The rabbit monoclonal anti-human sst 3 antibody 
UMB-5 was then employed for immunohistochemical 
stainings of a variety of human normal and neoplastic 
tissues. A set of tissue sections positively stained for sst 3 
was also incubated with UMB-5 pre-adsorbed with the 
respective immunizing peptide, which in all cases led to 
a complete abolition of the immunostaining (see insert in 
 fig. 1 c). For comparison of the staining patterns, adjacent 
sections were stained with the rabbit monoclonal anti-
human sst 3 antibody UMB-5 and the rabbit polyclonal 
anti-human sst 3 antibody {4823}, which are directed to 
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 Fig. 3. Analysis of the specificity of the monoclonal rabbit anti-
human sst 3 antibody UMB-5.  a Western blot analysis of mem-
brane preparations from HEK-293 cells stably transfected with 
the human sst 2A , sst 3 or sst 5 receptors. Samples were separated 
on 7.5% SDS polyacrylamide gels and blotted onto PVDF mem-
branes. Membranes were then incubated with the rabbit mono-
clonal anti-human sst 3 antibody UMB-5. Blots were developed 
using enhanced chemiluminescence. Ordinate: migration of 
protein molecular weight markers (M r  ! 10 –3 ). Note that UMB-
5 selectively detected only its targeted sst 3 receptor and did not 
cross-react with sst 2A or sst 5 .  b Western blot analysis of mem-
brane preparations from pituitaries from human autopsy. Soma-
tostatin receptors were enriched using wheat germ lectin agarose 
beads and either not deglycosylated (–) or subjected to enzymat-
ic deglycosylation using PNGase F (+). Blots were then immu-
noblotted with the rabbit monoclonal anti-human sst 3 antibody 
UMB-5 and developed using enhanced chemiluminescence.  c 
Immunocytochemistry of HEK-293 cells stably transfected with 
the human sst 3 receptor. Cells were grown on coverslips over-
night and either not exposed or exposed to 1   M somatosta-
tin-14 (SS-14), 1   M octreotide or 1   M pasireotide for 30 min, 
subsequently fixed and immunofluorescently stained with the 
rabbit monoclonal anti-human sst 3 antibody UMB-5. Specimens 
were then examined by confocal microscopy. Representative re-
sults from one of three independent experiments are shown. 
Scale bar = 20   m. 
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different carboxyl-terminal epitopes of the human sst 3 
receptor. As depicted in  figures 1 a–d, both antibodies 
yielded similar staining patterns in pancreatic islets and 
pheochromocytomas, two previously described promi-
nent localizations of the sst 3 receptor  [21] . However, in 
many cases, the monoclonal antibody UMB-5 yielded a 
more distinct plasma membrane staining ( fig.  1 e–h). 
Prominent sst 3 immunoreactivity was found in distinct 
cell populations of the anterior pituitary, pancreatic islets 
( fig. 1 c), enteric ganglion cells of the intestine ( fig. 1 e, ar-
rowheads), zona fasciculata and zona reticularis of the 
adrenal cortex ( fig. 1 f) as well as in the adrenal medulla. 
In addition, single strongly stained round-shaped cells 
were observed, scattered throughout the lamina propria 
mucosae of the gut ( fig.  1 e, arrows) or throughout the 
stroma of various malignant tissues like renal, prostate, 
breast, cervix, or ovarian tumors, probably representing 
mast cells.
 The presence of sst 3 immunoreactivity in the human 
tumor samples investigated is summarized in  table 1 . Ex-
amples of typical immunostainings are shown in  figure 
1 and  2 . In many positive cases, the immunostaining was 
predominantly localized at the plasma membrane of the 
tumor cells. However, in all sst 3 -expressing tumor enti-
ties investigated, not only a marked intraindividual het-
erogeneity, but also a huge interindividual variability 
both in the percentage of positive cells and in the inten-
sity of immunostaining was noticed ( table 1 ). Strong sst 3 
expression was seen in all pituitary adenomas, including 
non-functioning, ACTH- and GH-producing adenomas 
( table 1 ;  fig. 2 ). Interestingly, non-functioning adenomas 
did not exhibit any detectable or noticeable sst 2A or sst 5 
Table 1.  Presence of sst3 in different human tumor samples as determined by the prevalence and the immuno-
reactivity score (IRS) according to Remmele and Stegner [24]
Tumor type (total number of cases) sst3
positive cases, n (%)
IRS sst3
mean min. max.
Pituitary adenoma (41) 41 (100) 9.0 5 12
Non-functioning adenoma (6) 6 (100) 8 8 8
ACTH adenoma (8) 8 (100) 11.6 10 12
GH adenoma (27) 27 (100) 8.7 5 12
Glioblastoma (6) 4 (67) 2.1 0 6
Pancreatic adenocarcinoma (10) 6 (60) 1.9 0 4.5
Renal clear cell carcinoma (9) 0 (0) 0 0 0
Pheochromocytoma (13) 13 (100) 5.0 4 7.5
Neuroendocrine tumors (67) 56 (84) 4.8 0 12
of the lung (2) 2 (100) 6.0 4 8
of the gut (31) 26 (84) 4.7 0 12
Insulinoma (5) 5 (100) 7.3 4.5 8
Lymph node MTS (16) 14 (88) 5.3 0 12
Liver MTS (13) 9 (69) 3.3 0 12
Prostate adenocarcinoma (9) 0 (0) 0 0 0
Breast carcinoma (12) 4 (33) 2.7 0 12
Invasive ductal carcinoma (8) 0 (0) 0 0 0
Invasive lobular carcinoma (2) 2 (100) 5.3 4.5 6
Solid neuroendocrine carcinoma (2) 2 (100) 11.0 10 12
Cervix carcinoma (11) 4 (36) 1.7 0 6
Squamous cell carcinoma (7) 0 (0) 0 0 0
Adenocarcinoma (3) 3 (100) 4.2 3 5
Neuroendocrine tumor (1) 1 (100) 6.0 6 6
Ovarian tumors (12) 7 (58) 1.8 0 4.5
Serous-papillary adenocarcinoma (5) 1 (20) 1.8 0 4
Granulosa cell tumor (4) 3 (75) 1.8 0 4.5
Rhabdomyosarcoma (2) 2 (100) 3.5 2.5 4.5
Brenner tumor (1) 1 (100) 3.0 3 3
MT S = Metastases.
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expression ( fig.  2 , top panel). In the majority of the 
ACTH-producing adenomas, sst 3 and sst 5 were present 
( fig. 2 , middle panel). In contrast, all GH-producing ad-
enomas expressed sst 3 and sst 5 and in   65% of cases 
sst 2A as well ( fig. 2 , bottom panel). In addition, all cases 
of pheochromocytoma exhibited a noticeable sst 3 ex-
pression ( table 1 ;  fig. 1 d). About 85% of neuroendocrine 
tumors and their metastases were sst 3 positive, amongst 
them all insulinomas ( table 1 ;  fig. 1 g). The sst 3 receptor 
was also detectable in many glioblastomas, pancreatic 
adenocarcinomas, breast carcinomas (both investigated 
cases of invasive lobular and solid neuroendocrine car-
cinomas), cervix carcinomas (all cases of adenocarcino-
mas and the tumor with neuroendocrine differentiation) 
as well as ovarian tumors ( table 1 ;  fig. 1 h). No immuno-
staining for sst 3 was observed in renal clear cell carcino-
mas, prostate adenocarcinomas, invasive ductal carcino-
mas of the breast, and squamous cell carcinomas of the 
cervix uteri ( table 1 ).
 Discussion 
 In an effort to provide a monoclonal antibody that can 
be used for immunohistochemical staining of human sst 3 
receptors, we extensively characterized the novel rabbit 
monoclonal anti-human sst 3 antibody UMB-5. We show 
that the very carboxyl-terminal tail of human sst 3 can 
serve as an epitope for the generation of a rabbit mono-
clonal antibody that effectively stains formalin-fixed, 
paraffin-embedded human tissues. There are several 
lines of evidence indicating that UMB-5 specifically de-
tects its targeted receptor and does not cross-react. First, 
in Western blot analyses, UMB-5 selectively detected its 
cognate receptor and did not cross-react with other pro-
teins present in crude extracts from sst 2A - or sst 3 -trans-
fected cells. Second, enzymatic deglycosylation of the re-
ceptor revealed a distinct band at a lower molecular 
weight, corresponding to the expected molecular weight 
of the deglycosylated receptor. Third, the antibody yield-
ed a distinct staining of the cell surface of sst 3 -transfected 
cells. As expected from previous investigations with the 
polyclonal antibody {4823}  [25] , incubation with soma-
tostatin-14 induced a translocation of the receptor from 
the plasma membrane into the cytosol, indicating ago-
nist-induced endocytosis. A similar result was obtained 
with the pan-somatostatin analog pasireotide, whereas 
octreotide, which displays considerable lower affinity to 
sst 3 , was not able to cause internalization of the receptor. 
Fourth, UMB-5 yielded highly efficient immunostaining 
of formalin-fixed, paraffin-embedded tissue samples 
with similar staining patterns as those observed with the 
polyclonal rabbit anti-human sst 3 antibody {4823}, but 
with more distinct plasma membrane staining. Finally, 
preadsorption of UMB-5 with its immunizing peptide re-
sulted in complete abolition of immunostaining detected 
in tissue sections.
 In normal human tissues, the rabbit monoclonal anti-
body UMB-5 revealed a strong staining of distinct cell 
populations in anterior pituitary, pancreatic islands, ad-
renal cortex and medulla, enteric ganglia and mast cells. 
The findings with respect to anterior pituitary, pancreas, 
and adrenal tissue are in line with previous findings ob-
tained with polyclonal antibodies or by mRNA analysis 
 [4, 21, 26–28] . The presence of sst 3 in enteric ganglion 
cells and mast cells (identified by double-labeling experi-
ments showing the presence of mast cell protease-1 in 
these cells) has been recently demonstrated also by im-
munohistochemical investigations in the ileum of mice 
 [29, 30] .
 With respect to neoplastic human tissue, the present 
study revealed a high prevalence of sst 3 in different types 
of pituitary adenoma, namely in non-functioning adeno-
ma. Similar results have been shown previously by means 
of receptor autoradiography and mRNA analysis  [28, 31–
35] . The high prevalence of sst 3 in comparison to sst 2 and 
sst 5 found in the present investigation in non-functioning 
adenoma is also in line with clinical findings showing an 
insensitivity of the majority of the non-functioning ade-
noma to octreotide or lanreotide therapy and a higher 
efficacy of pasireotide treatment  [33, 36–38] . In the lit-
erature, however, also contradictory results on sst recep-
tor expression in non-functioning adenoma have been 
reported  [39, 40] . These discrepancies may be related to 
the PCR methodology and to the antibodies (monoclonal 
vs. polyclonal antibodies) used in the latter investiga-
tions.
 Also the high prevalence of sst 3 in pheochromocyto-
ma and neuroendocrine tumors found in our investiga-
tions with UMB-5 corresponds well to earlier data ob-
tained with polyclonal antibodies  [4, 21, 27, 41] . In con-
trast to these previous investigations showing primarily 
cytoplasmic immunoreactivity, the present study re-
vealed a predominance of plasma membrane staining. In 
accordance with data from the literature obtained with 
polyclonal antibodies or by means of mRNA analysis 
 [42–46] , our investigations revealed also a frequent pres-
ence of the sst 3 receptor in glioblastoma, pancreatic ade-
nocarcinoma, and in breast, cervix uteri, and ovarian tu-
mors.
 Novel Rabbit Monoclonal Anti-Human 
sst 3 Antibody UMB-5 
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 In conclusion, we have generated and characterized a 
novel rabbit monoclonal anti-human sst 3 antibody, which 
enables both immunocytochemistry and immunoblot-
ting experiments as well as the visualization of sst 3 recep-
tors in human formalin-fixed, paraffin-embedded tis-
sues during routine histopathological examinations. To 
our best knowledge, this is the first monoclonal anti-hu-
man sst 3 antibody yielding a predominance of plasma 
membrane staining in human tissue samples. In compar-
ison to currently available polyclonal antibodies, the 
monoclonal antibody UMB-5 has the advantage that it 
can be produced in unlimited amounts for an unlimited 
time in always identical high quality. The sst 3 receptor 
was localized at a high prevalence in non-functioning 
and in hormonally active pituitary adenomas, in neuro-
endocrine tumors and also in different other solid neo-
plasms, which may open up new routes for diagnostic and 
therapeutic intervention, both pharmacologically and 
with radiolabeled sst 3 receptor ligands.
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